Cannabis use in people with type 1 diabetes can raise DKA risk and trigger a condition with similar symptoms called HK-CHS. Monitoring glucose, understanding effects,...

This article details Mounjaro's efficacy in type 2 diabetes management, highlighting the drug’s ability to significantly reduce A1C and body weight. Read about the...

In case you missed them, here are our top stories from October 2023 that cover upcoming therapies, groundbreaking research, and more.

Medtronic unveils Simplera, the latest CGM approved in Europe for people with diabetes ages two and older. A sleek, disposable device, Simplera rivals the Dexcom G7 and...

Researchers find automated insulin delivery (AID) systems, the MiniMed 780G and Omnipod 5, showed significant improvement in time in range for everyday users. This real-...

Explore the profound issue of diabetes stigma and steps we can take to combat it. From the Language Matters movement to personal stories and global pledges, discover how...

Determining ideal carbohydrate intake for those with type 1 diabetes remains complex. Two studies at EASD 2023 highlight the benefits of a plant-based diet and...

Data presented at EASD 2023 reveals orforglipron's potential in type 2 diabetes management. The new oral GLP-1 medication demonstrated significant reductions for A1C and...

People with type 1 diabetes face higher kidney risks, yet treatments approved for type 2 aren't FDA approved for them due to clinical trial gaps. The EASD 2023 panel...

Despite advancements in diabetes treatment, emergency department visits among adults with diabetes surged 21% from 2014-2018. The 2023 EASD Conference unveils updated...

Survodutide, a GLP-1/glucagon dual receptor agonist, shows promising weight loss results in a clinical trial. The injectable medication, developed by Zealand and...

Experts addressed rising rates of cardiovascular disease in children with diabetes at EASD 2023, emphasizing prevention and finding new biomarkers for early...

New research from the ReTUNE study of people with type 2 diabetes at a normal weight by Dr. Roy Taylor, University of Newcastle, found that type 2 diabetes is not caused...

At the 59th European Association for the Study of Diabetes in Germany, an expert panel discussed the tremendous cardiovascular health benefits of limiting body weight...

Tirzepatide (sold as Mounjaro) is more effective than semaglutide (Ozempic) for both blood glucose control and weight loss, according to a new analysis.

The newest study of once-weekly insulins showed that insulin icodec led to similar reductions in A1C and similar time in range compared to once-daily Tresiba (degludec).

Diabetic foot ulcers are a common and costly complication for people with diabetes. ON101 is a promising new topical treatment anticipated for FDA approval in the coming...

People dealing with access to food are more likely to have overweight, obesity, or type 2 diabetes. If you face barriers to accessing nutritious foods, there are...

Research shows screening children ages 2-6 best predicts childhood type 1 diabetes. Early screening also leads to more timely treatment, better outcomes, and reduced...

The debate over how many carbohydrates people should consume has raged for decades. Experts share their perspectives on low, very low, and moderate carb diets for ideal...